MEI Pharma Inc. (MEIP)

4.49
NASDAQ : Health Technology
Prev Close 4.49
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.79 / 5.14
Avg Volume 468.70K
Exchange NASDAQ
Shares Outstanding 70.33M
Market Cap 298.19M
EPS 0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

MEI Pharma Presents Clinical Data For ME-344 In HER2 Negative Breast Cancer Patients At The 2018 American Society Of Clinical Oncology (ASCO) Annual Meeting

MEI Pharma Presents Clinical Data For ME-344 In HER2 Negative Breast Cancer Patients At The 2018 American Society Of Clinical Oncology (ASCO) Annual Meeting

-- ME-344 Mitochondrial Inhibitor in Combination with Avastin Demonstrates Inhibition of Tumor Proliferation in HER2 Negative Breast Cancer Patients --

MEI Pharma Reaches Analyst Target Price

In recent trading, shares of MEI Pharma Inc have crossed above the average analyst 12-month target price of $3.17, changing hands for $3.30/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

MEI Pharma And Helsinn Group Announce Successful Interim Analysis Of Pracinostat/Azacitidine Phase 2 Combination Study In Higher Risk Myelodysplastic Syndrome (MDS) Patients

-- Predefined Patient Retention Threshold Met: 10% Early Discontinuation Rate Due to Adverse Events Supports Expansion of Patient Enrollment --

MEI Pharma Interim Data Review Supports Continuation Of Clinical Study Evaluating ME-344 In Patients With Breast Cancer

MEI Pharma Interim Data Review Supports Continuation Of Clinical Study Evaluating ME-344 In Patients With Breast Cancer

Interim data further support potential of ME-344 to reverse resistance to antiangiogenic therapy

MEI Pharma Announces Study Of Clinical Stage Oral CDK Inhibitor Voruciclib Published In Nature Scientific Reports

MEI Pharma Announces Study Of Clinical Stage Oral CDK Inhibitor Voruciclib Published In Nature Scientific Reports

New Preclinical Studies Demonstrate Repression of MCL-1 and Sensitization to BCL-2 Inhibition in Diffuse Large B-Cell Lymphoma

Interesting MEIP Call Options For December 16th

Interesting MEIP Call Options For December 16th

Investors in MEI Pharma Inc saw new options begin trading this week, for the December 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 136 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

MEI Pharma (MEIP) Stock Soars on Leukemia Treatment's Phase 2 Trial Results

MEI Pharma (MEIP) Stock Soars on Leukemia Treatment's Phase 2 Trial Results

MEI Pharma (MEIP) stock is surging in early-morning trading on Monday, after the oncology company announced positive results from its leukemia treatment's Phase II trial.

MEI Pharma (MEIP) Stock Rises Today Following Monday's Sharp Decline

MEI Pharma (MEIP) Stock Rises Today Following Monday's Sharp Decline

Shares of MEI Pharma (MEIP) were up in late morning trading Tuesday as investors swooped into the stock following its significant decline on Monday.

MEI Pharma (MEIP) Stock Plummets to 52-Week Low After Cancer Drug Trial Results

MEI Pharma (MEIP) Stock Plummets to 52-Week Low After Cancer Drug Trial Results

Shares of MEI Pharma (MEIP) plunged to a one-year low on Monday after the company announced its cancer drug Pracinostat failed to meet its main goal in a mid-stage trial.

First Week of April 17th Options Trading For MEI Pharma (MEIP)

First Week of April 17th Options Trading For MEI Pharma (MEIP)

Investors in MEI Pharma Inc saw new options become available this week, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MEIP options chain for the new April 17th contracts and identified one put and one call contract of particular interest.

4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More

4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More

Keep these under-$10 biotech stocks on your breakout trading radar.

5 Under-$10 Health Care Stocks Setting Up to Trade Higher

5 Under-$10 Health Care Stocks Setting Up to Trade Higher

These setups often produce monster moves higher in very short time frames.

Oversold Conditions For MEI Pharma (MEIP)

Oversold Conditions For MEI Pharma (MEIP)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

3 Under-$10 Health Care Stocks Triggering Breakout Trades

3 Under-$10 Health Care Stocks Triggering Breakout Trades

Keep these health care stocks under $10 on your breakout trading radar.

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks look ready to break out and trade higher from current levels.

3 Biotech Stocks Under $10 to Trade for Breakouts

3 Biotech Stocks Under $10 to Trade for Breakouts

These under-$10 biotech stocks are within range of triggering breakout trades.

4 Biotech Stocks Under $10 to Watch for Breakout Trades

4 Biotech Stocks Under $10 to Watch for Breakout Trades

These under-$10 biotech stocks are within range of triggering breakout trades.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering breakout trades.

Relative Strength Alert For MEI Pharma

Relative Strength Alert For MEI Pharma

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

3 Stocks Spiking on Big Volume

3 Stocks Spiking on Big Volume

Unusual volume can be a major signal that hedge funds and momentum traders are piling into a stock ahead of a catalyst.

4 Stocks Under $10 Triggering Breakouts

4 Stocks Under $10 Triggering Breakouts

These under-$10 stocks are within range of triggering breakout trades.

5 Stocks Ready to Break Out

5 Stocks Ready to Break Out

These stocks look ready to break out and trade higher from current levels.

TheStreet Quant Rating: D (Sell)